INTRODUCTION
The relationship between the plasma nonalbumin-bound (''free'') bilirubin concentration and bilirubin toxicity (kernicterus) in newborns with unconjugated hyperbilirubinemia is highly controversial. 1 Treatment of jaundiced newborns in the United States is based primarily on empirically derived plasma total bilirubin concentrations, 2 and bilirubin-albumin binding measurements such as the ''free'' bilirubin concentration are rarely considered or performed. The lack of robust criteria for treating jaundice, coupled with the risks of exchange transfusion and ease of using phototherapy, makes it possible to rationalize almost any treatment scheme and even the occasional case of kernicterus. 1 However, is the status quo really serving our patients? 3 Would measuring the ''free'' bilirubin improve our clinical management of jaundiced newborns?
PATHOPHYSIOLOGY OF KERNICTERUS
Clinical experience and extensive research show the pathophysiology of kernicterus to be extremely complex. The risk of developing kernicterus is proportional to (indicated by the symbol / in the expressions below) the rate of bilirubin production (P), the total bilirubin concentration (T), and the duration of bilirubin exposure (D). It is inversely proportional to factors such as the rate of bilirubin excretion (E), gestational age (G), bilirubin solubility (S), the plasma albumin concentration (A), the bilirubin-albumin equilibrium binding constant (K), blood-brain barrier integrity (B), neuronal integrity (N), and metabolic integrity (M). 1, 4 Expressing risk as a proportion illustrates how difficult it is to ascertain the true risk of kernicterus in any jaundiced newborn:
Expressing risk as a proportion implies that there is a mathematical paradigm quantifying the relationship between the risk of kernicterus and the risk factors. The paradigm is likely to be complex, and the impact of many of the factors on the risk of developing kernicterus has not been quantified. The risk of kernicterus in a 32-week gestation baby, for example, is about fourfold that in a 36-week baby, 5 but the degree to which factors such as B, N, and M alter risk is currently unknown. Whether the relationship between these factors and risk of kernicterus can be quantified is unknown, but the importance of considering as many of the factors as possible cannot be overstated. Kernicterus may occur in as few as 1/50,000 otherwise well, term newborns, 6 and in as many 1% to 3% of untreated premature newborns (#G). 5, 7 Theoretically, the ''free'' bilirubin (b) contains information about risk factors S, T, A, and K. Bilirubin solubility decreases (#S) as the ''free'' bilirubin increases, 8 making solubility proportional to 1/b, and by mass action (at clinically relevant concentrations), b is proportional to TÄAÁK, simplifying the proportional expression to:
According to the ''free'' bilirubin hypothesis, 4 the plasma total and ''free'' bilirubin (b p ) establish a steady state across the blood-brain barrier (B) and the neuronal cell membrane (C) with the ''free'' bilirubin (b i ) in the interstitial fluid (IF) and ''free'' bilirubin (b n ) in the neuron as shown in the following scheme:
At nontoxic bilirubin levels, the ''free'' bilirubin in these compartments is also in a steady state with bilirubin bound to albumin, membranes, and cell organelles. Bilirubin toxicity occurs
The relevance of plasma bilirubin -albumin binding and, in particular, the nonalbumin -bound or ''free'' bilirubin concentration to neonatal bilirubin toxicity is controversial. The pivotal role that ''free'' bilirubin played in the bilirubin toxicity that occurred following administration of sulfisoxazole or benzyl alcohol to jaundiced newborns, and the correlation of ''free'' bilirubin with bilirubin -induced changes in the auditory brainstem response are strong support for measuring ''free'' bilirubin when evaluating neonatal jaundice. Original Article
if the ''free'' bilirubin reaches levels where it becomes insoluble, and/or membranes and organelles are sufficiently saturated to disrupt function. The risk of bilirubin toxicity will therefore be proportional to the plasma ''free'' bilirubin, but modulated by the other risk factors present such as gestation, metabolic integrity (e.g., acidosis), and so forth. The ''free'' bilirubin hypothesis was developed to explain an outbreak of kernicterus in premature newborns given sulfisoxazole as prophylaxis for infection. 7, 9 As seen in the Table 1 , when sulfisoxazole was given, kernicterus frequently occurred at total bilirubin concentrations between 12 and 18 mg/dl (''low'' total bilirubin kernicterus). The drug was shown to compete with bilirubin for albumin binding sites, 9 increasing the plasma ''free'' bilirubin ("b p ) and, in susceptible infants, perturbing the steady state sufficiently to cause toxic neuronal ''free'' bilirubin levels ("b n ). Susceptible newborns had bilirubin loads that were large enough to produce plasma total bilirubin concentrations above 12 mg/dl with drug present (Table 1) . At a total bilirubin of 12 mg/dl with drug present, the ''free'' bilirubin would exceed 1 g/dl (17 nmol/l). 10 The sulfisoxazole experience and supporting animal data 11 lead to the development of several bilirubin-albumin binding tests that measured ''free'' albumin or ''free'' bilirubin. 12 The early clinical experience with these tests was mixed, 13 and the advent of Rhogam, phototherapy, and the aggressive use of exchange transfusion reduced kernicterus to levels making prospective studies to evaluate bilirubin binding tests problematic.
1,2 Furthermore, questions about the validity of the ''free'' bilirubin hypothesis were raised by animal data suggesting that albumin-bound, rather than ''free,'' bilirubin crosses the blood-brain barrier 14 and by an outbreak of ''low'' bilirubin kernicterus in sick, premature newborns receiving benzyl alcohol, which does not bind to albumin. 15 Kernicterus at autopsy was found in about 20% of newborns who died after inadvertently receiving large amounts of benzyl alcohol as a preservative in intravenous flush solutions and medications. A prospective study in progress at the time found no significant correlation between '' free'' bilirubin levels and kernicterus in these babies. 16 In retrospect, however, this apparently devastating evidence against the ''free'' bilirubin hypothesis did not disprove it. 10, 17 Unappreciated at the time of the benzyl alcohol exposure was the accumulation of large amounts of benzoate, a metabolite of benzyl alcohol, in these babies. 15 Benzoate, like sulfisoxazole, competes with bilirubin for albumin-binding sites and, like sulfisoxazole, was present in sufficient amounts to produce ''toxic'' levels of ''free'' bilirubin. Unfortunately, the ''free'' bilirubin measurements in the prospective study were rendered inaccurate by the 40-fold sample dilution used, which would nearly eliminate the bilirubin-displacing effect of the weakly binding benzoate. 17 Subsequent studies in premature newborns not receiving benzyl alcohol have found a significant correlation between kernicterus and the ''free'' (but not total) bilirubin, 18 and animal studies now show that the ''free'' bilirubin is the major determinant of bilirubin toxicity even when the bilirubin-albumin complex crosses the blood-brain barrier. 19 The clinical experiences with both sulfisoxazole and benzyl alcohol strongly support the ''free'' bilirubin hypothesis, and additional evidence for the hypothesis has been obtained using the auditory brainstem response (ABR) as a marker for bilirubin toxicity.
Bilirubin induces predictable, progressive, often-reversible changes in ABR wave latency and amplitude that correlate significantly with the ''free,'' but not the total, bilirubin in both term and premature human newborns. 20, 21 These findings provide a strong impetus for reconsidering the use of bilirubin-albumin binding measurements in the evaluation of jaundiced newborns, but clinical use of ''free'' bilirubin measurements requires a reliable method for measuring ''free'' bilirubin as well as ''free'' bilirubin reference values (the values at which kernicterus is likely).
There is a commercially available analyzer for measuring ''free'' bilirubin by the peroxidase method, and spectral evidence indicates that the measured ''free'' bilirubin is at least proportional to the true ''free'' bilirubin. 12 The test is inaccurate when weakly binding bilirubin competitors (e.g., benzoate) are present, no correction is made for rate-limiting dissociation of bilirubin from albumin, or high concentrations of antioxidants, conjugated bilirubin, or free radical-producing drugs are present. A recent modification of the method 22 overcomes many of these limitations, and the modified test would have detected the elevated ''free'' bilirubin levels in the babies receiving sulfisoxazole and benzyl alcohol. 10, 17 The ABR data and clinical experiences with sulfisoxazole and benzyl alcohol provide some information about ''toxic'' levels of ''free'' bilirubin. In premature newborns, bilirubin-induced ABR abnormalities begin above a ''free'' bilirubin level of about 0.5 g/dl, 21 and kernicterus becomes likely above 1 g/dl. 10, 18 In term newborns, bilirubin-induced ABR changes do not occur until the ''free'' bilirubin exceeds about 1 g/dl 20 -a level that is toxic in the premature. 18 The gestational differences in the threshold ''free'' bilirubin-producing ABR changes indicate that there is no single ''toxic,'' ''free'' bilirubin level, further underscoring the futility of trying to establish ''free'' bilirubin reference values by prospective study using some overt measure of kernicterus.
A feasible alternative would be to obtain ''free'' bilirubin reference values by measuring ''free'' bilirubin population parameters (mean, standard deviation, and so forth) at the empirically determined total bilirubin reference values currently in use. 2 For example, clinical experience indicates that kernicterus is prevented in tiny premature 
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Bilirubin -Albumin Binding Ahlfors newborns if total bilirubin is kept below 10 mg/dl. 2 By inference, the population mean ''free'' bilirubin level at that total bilirubin can be considered a ''free'' bilirubin reference value for these babies. Comparing ''free'' bilirubin measurements with the population mean provides important information on which to base treatment decisions. Exchange transfusion might be warranted at total bilirubins less than 10 mg/dl if the ''free'' bilirubin is substantially higher than the mean for the population. Conversely, phototherapy might be more appropriate at a total bilirubin of 10 mg/dl when the ''free'' bilirubin level is well below the population mean. This approach integrates the ''free'' bilirubin and the total bilirubin, rather than considering them adversaries. 4 In summary, there is strong evidence that ''free'' bilirubin plays an important role in the pathogenesis of kernicterus, and we should try to incorporate it into the evaluation of jaundiced newborns. A reliable method for measuring ''free'' bilirubin is available, and reference values based on current total bilirubin reference values can be determined. The aphorism ''more mistakes in medicine are made by not looking than by not knowing'' seems apropos. The time has come to re-examine rather than ignore the ''free'' bilirubin.
